Quick Answer
LIPELLA PHARMACEUTICALS INC. reported Cash And Cash Equivalents At Carrying Value of $2.18 million for the year ending 2024.
- LIPELLA PHARMACEUTICALS INC. showed a decrease of -33.7% in Cash And Cash Equivalents At Carrying Value from 2023 to 2024.
- This data is from LIPELLA PHARMACEUTICALS INC.'s annual report (Form 10-K), filed with the SEC on March 28, 2025.
- XBRL data for this metric is available from 2021 to 2024 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2023: $4.02 million | Q2 2023: $3.11 million | Q3 2023: $2.41 million | Q1 2024: $2.11 million | Q2 2024: $1.19 million | Q3 2024: $1.35 million | Q4 2024: $2.18 million | Q1 2025: $4.23 million | Q2 2025: $2.78 million | Q3 2025: $1.86 million.
- Over the full 4 years of available data (2021 to 2024), LIPELLA PHARMACEUTICALS INC.'s Cash And Cash Equivalents At Carrying Value has grown by 54.5%.
- Historical annual values: Fiscal year 2024: $2.18 million | Fiscal year 2023: $3.29 million | Fiscal year 2022: $5.12 million | Fiscal year 2021: $1.41 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: